Oncode Institute, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands.
Biochem Soc Trans. 2020 Apr 29;48(2):479-497. doi: 10.1042/BST20190535.
Eukaryotic life depends upon the interplay between vast networks of signaling pathways composed of upwards of 109-1010 proteins per cell. The integrity and normal operation of the cell requires that these proteins act in a precise spatial and temporal manner. The ubiquitin system is absolutely central to this process and perturbation of its function contributes directly to the onset and progression of a wide variety of diseases, including cancer, metabolic syndromes, neurodegenerative diseases, autoimmunity, inflammatory disorders, infectious diseases, and muscle dystrophies. Whilst the individual components and the overall architecture of the ubiquitin system have been delineated in some detail, how ubiquitination might be successfully targeted, or harnessed, to develop novel therapeutic approaches to the treatment of disease, currently remains relatively poorly understood. In this review, we will provide an overview of the current status of selected small molecule ubiquitin system inhibitors. We will further discuss the unique challenges of targeting this ubiquitous and highly complex machinery, and explore and highlight potential ways in which these challenges might be met.
真核生物的生命活动依赖于由数量高达 10^9-10^10 个蛋白质组成的庞大信号通路网络的相互作用。细胞的完整性和正常运作要求这些蛋白质以精确的时空方式发挥作用。泛素系统是这一过程的绝对核心,其功能的紊乱直接导致了多种疾病的发生和发展,包括癌症、代谢综合征、神经退行性疾病、自身免疫性疾病、炎症性疾病、传染病和肌肉萎缩症等。虽然泛素系统的各个组成部分和整体结构已经被详细描述,但泛素化如何能够被成功靶向或利用,以开发针对疾病治疗的新的治疗方法,目前仍然相对了解甚少。在这篇综述中,我们将概述选定的小分子泛素系统抑制剂的现状。我们将进一步讨论靶向这种普遍存在且高度复杂的机制所面临的独特挑战,并探讨和强调可能克服这些挑战的方法。